Compare American Water Works Company Inc (AWK) vs Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Water Works Company Inc vs Bio-Rad Laboratories, Inc. Class A Common Stock — how do they compare? American Water Works Company Inc trades at $131.69 (market cap $25.69B), while Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.02B). The key difference: American Water Works Company Inc is far larger — about 3.2× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and American Water Works Company Inc pays a 2.72% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| AWK | BIO | |
|---|---|---|
Market Cap | $25.69B | $8.02B |
Sector | Utilities | Health |
52-Week High | $147.00 | $339.75 |
52-Week Low | $121.13 | $241.71 |
Enterprise Value | $41.25B | $7.84B |
Dividend Yield | 2.72% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About American Water Works Company Inc
American Water Works is the largest investor-owned U.S. water and wastewater utility, serving approximately 3.5 million customers in 16 states. It provides water and wastewater services to residential, commercial, and industrial customers and operates predominantly in regulated markets. The company's only nonregulated business is water services for military bases, which operates under long-term contracts.
Read more on AWK →About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →
